nodes	percent_of_prediction	percent_of_DWPC	metapath
Trazodone—SLC6A4—conduct disorder	0.531	0.566	CbGaD
Trazodone—HTR2A—conduct disorder	0.408	0.435	CbGaD
Trazodone—ORM1—saliva—conduct disorder	0.00273	0.48	CbGeAlD
Trazodone—SLC6A4—Serotonin Transporter Activity—MAOA—conduct disorder	0.00252	0.0547	CbGpPWpGaD
Trazodone—HTR2B—Serotonin receptors—HTR2A—conduct disorder	0.00165	0.0357	CbGpPWpGaD
Trazodone—Vilazodone—SLC6A4—conduct disorder	0.00149	0.159	CrCbGaD
Trazodone—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.00134	0.029	CbGpPWpGaD
Trazodone—HTR2C—Serotonin receptors—HTR2A—conduct disorder	0.00133	0.0288	CbGpPWpGaD
Trazodone—HTR2A—autonomic nervous system—conduct disorder	0.00126	0.222	CbGeAlD
Trazodone—HTR2B—Monoamine GPCRs—DRD4—conduct disorder	0.00112	0.0244	CbGpPWpGaD
Trazodone—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—conduct disorder	0.00109	0.0237	CbGpPWpGaD
Trazodone—HTR2B—Amine ligand-binding receptors—DRD4—conduct disorder	0.000945	0.0205	CbGpPWpGaD
Trazodone—Ziprasidone—DRD4—conduct disorder	0.000938	0.1	CrCbGaD
Trazodone—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.000911	0.0198	CbGpPWpGaD
Trazodone—HTR2C—Monoamine GPCRs—DRD4—conduct disorder	0.000907	0.0197	CbGpPWpGaD
Trazodone—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—conduct disorder	0.000883	0.0191	CbGpPWpGaD
Trazodone—HTR2A—Monoamine GPCRs—DRD4—conduct disorder	0.000787	0.0171	CbGpPWpGaD
Trazodone—HRH1—Monoamine GPCRs—DRD4—conduct disorder	0.000786	0.017	CbGpPWpGaD
Trazodone—ADRA1A—Monoamine GPCRs—DRD4—conduct disorder	0.000771	0.0167	CbGpPWpGaD
Trazodone—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000766	0.0166	CbGpPWpGaD
Trazodone—HTR2C—Amine ligand-binding receptors—DRD4—conduct disorder	0.000762	0.0165	CbGpPWpGaD
Trazodone—HTR2B—Monoamine GPCRs—HTR2A—conduct disorder	0.000733	0.0159	CbGpPWpGaD
Trazodone—Aripiprazole—DRD4—conduct disorder	0.000733	0.0782	CrCbGaD
Trazodone—ADRA2A—Monoamine GPCRs—DRD4—conduct disorder	0.000716	0.0155	CbGpPWpGaD
Trazodone—HTR2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000662	0.0143	CbGpPWpGaD
Trazodone—HRH1—Amine ligand-binding receptors—DRD4—conduct disorder	0.00066	0.0143	CbGpPWpGaD
Trazodone—ADRA1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000648	0.014	CbGpPWpGaD
Trazodone—HTR2B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000616	0.0134	CbGpPWpGaD
Trazodone—ADRA2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000602	0.0131	CbGpPWpGaD
Trazodone—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.000595	0.0129	CbGpPWpGaD
Trazodone—HTR2C—Monoamine GPCRs—HTR2A—conduct disorder	0.000591	0.0128	CbGpPWpGaD
Trazodone—Ziprasidone—SLC6A4—conduct disorder	0.000563	0.0601	CrCbGaD
Trazodone—HRH1—Monoamine GPCRs—HTR2A—conduct disorder	0.000513	0.0111	CbGpPWpGaD
Trazodone—ADRA1A—Monoamine GPCRs—HTR2A—conduct disorder	0.000503	0.0109	CbGpPWpGaD
Trazodone—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0005	0.0108	CbGpPWpGaD
Trazodone—HTR2C—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000497	0.0108	CbGpPWpGaD
Trazodone—Nefazodone—SLC6A4—conduct disorder	0.000473	0.0505	CrCbGaD
Trazodone—Loxapine—DRD4—conduct disorder	0.000469	0.0501	CrCbGaD
Trazodone—ADRA2A—Monoamine GPCRs—HTR2A—conduct disorder	0.000467	0.0101	CbGpPWpGaD
Trazodone—Quetiapine—DRD4—conduct disorder	0.000458	0.0489	CrCbGaD
Trazodone—Aripiprazole—SLC6A4—conduct disorder	0.00044	0.0469	CrCbGaD
Trazodone—Ziprasidone—HTR2A—conduct disorder	0.000432	0.0462	CrCbGaD
Trazodone—HRH1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000431	0.00934	CbGpPWpGaD
Trazodone—ADRA1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000423	0.00917	CbGpPWpGaD
Trazodone—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.000414	0.00898	CbGpPWpGaD
Trazodone—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.000399	0.00866	CbGpPWpGaD
Trazodone—Clozapine—DRD4—conduct disorder	0.000394	0.0421	CrCbGaD
Trazodone—ADRA2A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000393	0.00852	CbGpPWpGaD
Trazodone—Zuclopenthixol—HTR2A—conduct disorder	0.000365	0.039	CrCbGaD
Trazodone—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000365	0.00792	CbGpPWpGaD
Trazodone—Nefazodone—HTR2A—conduct disorder	0.000363	0.0388	CrCbGaD
Trazodone—HTR2A—GPCRs, Other—DRD4—conduct disorder	0.00035	0.00758	CbGpPWpGaD
Trazodone—Aripiprazole—HTR2A—conduct disorder	0.000338	0.0361	CrCbGaD
Trazodone—HTR2B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000332	0.00719	CbGpPWpGaD
Trazodone—Thioproperazine—HTR2A—conduct disorder	0.00032	0.0342	CrCbGaD
Trazodone—SLC6A4—Circadian rythm related genes—DRD4—conduct disorder	0.000308	0.00668	CbGpPWpGaD
Trazodone—SLC6A4—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000302	0.00655	CbGpPWpGaD
Trazodone—Loxapine—SLC6A4—conduct disorder	0.000281	0.0301	CrCbGaD
Trazodone—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00028	0.00606	CbGpPWpGaD
Trazodone—Fluphenazine—HTR2A—conduct disorder	0.000272	0.0291	CrCbGaD
Trazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000269	0.00583	CbGpPWpGaD
Trazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000268	0.0058	CbGpPWpGaD
Trazodone—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000264	0.00572	CbGpPWpGaD
Trazodone—HTR2B—GPCR ligand binding—CGA—conduct disorder	0.000253	0.00548	CbGpPWpGaD
Trazodone—SLC6A4—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000246	0.00534	CbGpPWpGaD
Trazodone—HTR2C—brain—conduct disorder	0.000243	0.0427	CbGeAlD
Trazodone—HTR2A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000242	0.00524	CbGpPWpGaD
Trazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000232	0.00504	CbGpPWpGaD
Trazodone—HRH1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000232	0.00503	CbGpPWpGaD
Trazodone—SLC6A4—brain—conduct disorder	0.00023	0.0405	CbGeAlD
Trazodone—HTR2B—brain—conduct disorder	0.000228	0.0401	CbGeAlD
Trazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000228	0.00493	CbGpPWpGaD
Trazodone—Trifluoperazine—HTR2A—conduct disorder	0.000218	0.0232	CrCbGaD
Trazodone—HTR2B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000217	0.0047	CbGpPWpGaD
Trazodone—Loxapine—HTR2A—conduct disorder	0.000216	0.0231	CrCbGaD
Trazodone—Perphenazine—HTR2A—conduct disorder	0.000215	0.023	CrCbGaD
Trazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000211	0.00458	CbGpPWpGaD
Trazodone—Quetiapine—HTR2A—conduct disorder	0.000211	0.0225	CrCbGaD
Trazodone—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00021	0.00456	CbGpPWpGaD
Trazodone—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.000205	0.00444	CbGpPWpGaD
Trazodone—HTR1A—brain—conduct disorder	0.000205	0.036	CbGeAlD
Trazodone—HTR2C—GPCR ligand binding—CGA—conduct disorder	0.000204	0.00442	CbGpPWpGaD
Trazodone—CYP3A7—Biological oxidations—COMT—conduct disorder	0.000195	0.00424	CbGpPWpGaD
Trazodone—CYP3A7—Biological oxidations—MAOA—conduct disorder	0.000194	0.00421	CbGpPWpGaD
Trazodone—CYP3A7—Metapathway biotransformation—COMT—conduct disorder	0.000193	0.00418	CbGpPWpGaD
Trazodone—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.000189	0.00411	CbGpPWpGaD
Trazodone—ADRA1A—brain—conduct disorder	0.000189	0.0331	CbGeAlD
Trazodone—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000188	0.00407	CbGpPWpGaD
Trazodone—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000186	0.00403	CbGpPWpGaD
Trazodone—HRH1—IL-4 Signaling Pathway—EP300—conduct disorder	0.000183	0.00397	CbGpPWpGaD
Trazodone—HTR2B—G alpha (q) signalling events—HTR2A—conduct disorder	0.000183	0.00397	CbGpPWpGaD
Trazodone—HTR2A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000182	0.00394	CbGpPWpGaD
Trazodone—Clozapine—HTR2A—conduct disorder	0.000182	0.0194	CrCbGaD
Trazodone—HTR2A—GPCR ligand binding—CGA—conduct disorder	0.000177	0.00384	CbGpPWpGaD
Trazodone—HRH1—GPCR ligand binding—CGA—conduct disorder	0.000177	0.00383	CbGpPWpGaD
Trazodone—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000176	0.00381	CbGpPWpGaD
Trazodone—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000175	0.00379	CbGpPWpGaD
Trazodone—ADRA1A—GPCR ligand binding—CGA—conduct disorder	0.000173	0.00376	CbGpPWpGaD
Trazodone—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000172	0.00372	CbGpPWpGaD
Trazodone—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000164	0.00355	CbGpPWpGaD
Trazodone—ADRA2A—GPCR ligand binding—CGA—conduct disorder	0.000161	0.00349	CbGpPWpGaD
Trazodone—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000152	0.00329	CbGpPWpGaD
Trazodone—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000152	0.00329	CbGpPWpGaD
Trazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000151	0.00327	CbGpPWpGaD
Trazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00015	0.00325	CbGpPWpGaD
Trazodone—ADRA2A—G alpha (i) signalling events—DRD4—conduct disorder	0.000149	0.00323	CbGpPWpGaD
Trazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000149	0.00323	CbGpPWpGaD
Trazodone—HTR2C—G alpha (q) signalling events—HTR2A—conduct disorder	0.000148	0.0032	CbGpPWpGaD
Trazodone—HRH1—brain—conduct disorder	0.000146	0.0257	CbGeAlD
Trazodone—ADRA2A—brain—conduct disorder	0.000143	0.0252	CbGeAlD
Trazodone—HTR2B—GPCR downstream signaling—CGA—conduct disorder	0.000143	0.0031	CbGpPWpGaD
Trazodone—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000141	0.00307	CbGpPWpGaD
Trazodone—HTR2B—GPCR ligand binding—DRD4—conduct disorder	0.000141	0.00307	CbGpPWpGaD
Trazodone—CYP3A5—Biological oxidations—COMT—conduct disorder	0.000141	0.00306	CbGpPWpGaD
Trazodone—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.00014	0.00304	CbGpPWpGaD
Trazodone—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.000139	0.00302	CbGpPWpGaD
Trazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000138	0.003	CbGpPWpGaD
Trazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000132	0.00286	CbGpPWpGaD
Trazodone—SLC6A4—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00013	0.00283	CbGpPWpGaD
Trazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00013	0.00282	CbGpPWpGaD
Trazodone—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00013	0.00282	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—CGA—conduct disorder	0.00013	0.00281	CbGpPWpGaD
Trazodone—HRH1—G alpha (q) signalling events—HTR2A—conduct disorder	0.000128	0.00277	CbGpPWpGaD
Trazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000127	0.00276	CbGpPWpGaD
Trazodone—ADRA1A—G alpha (q) signalling events—HTR2A—conduct disorder	0.000126	0.00272	CbGpPWpGaD
Trazodone—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000123	0.00266	CbGpPWpGaD
Trazodone—HTR2A—brain—conduct disorder	0.000122	0.0214	CbGeAlD
Trazodone—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000121	0.00263	CbGpPWpGaD
Trazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000118	0.00257	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.000116	0.00251	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—CGA—conduct disorder	0.000115	0.0025	CbGpPWpGaD
Trazodone—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000115	0.00249	CbGpPWpGaD
Trazodone—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.000115	0.00249	CbGpPWpGaD
Trazodone—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000114	0.00248	CbGpPWpGaD
Trazodone—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000114	0.00247	CbGpPWpGaD
Trazodone—HTR2C—GPCR ligand binding—DRD4—conduct disorder	0.000114	0.00247	CbGpPWpGaD
Trazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000112	0.00243	CbGpPWpGaD
Trazodone—CYP2D6—brain—conduct disorder	0.000111	0.0195	CbGeAlD
Trazodone—SLC6A4—Circadian rythm related genes—EP300—conduct disorder	0.000107	0.00231	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.000105	0.00228	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—CGA—conduct disorder	0.000105	0.00227	CbGpPWpGaD
Trazodone—CYP2D6—Biological oxidations—COMT—conduct disorder	0.0001	0.00218	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—CGA—conduct disorder	0.0001	0.00217	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—CGA—conduct disorder	9.98e-05	0.00216	CbGpPWpGaD
Trazodone—CYP2D6—Biological oxidations—MAOA—conduct disorder	9.97e-05	0.00216	CbGpPWpGaD
Trazodone—HTR2A—GPCR ligand binding—DRD4—conduct disorder	9.91e-05	0.00215	CbGpPWpGaD
Trazodone—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	9.9e-05	0.00215	CbGpPWpGaD
Trazodone—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	9.89e-05	0.00214	CbGpPWpGaD
Trazodone—HRH1—GPCR ligand binding—DRD4—conduct disorder	9.89e-05	0.00214	CbGpPWpGaD
Trazodone—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	9.83e-05	0.00213	CbGpPWpGaD
Trazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.83e-05	0.00213	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—CGA—conduct disorder	9.79e-05	0.00212	CbGpPWpGaD
Trazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.78e-05	0.00212	CbGpPWpGaD
Trazodone—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	9.71e-05	0.0021	CbGpPWpGaD
Trazodone—ADRA1A—GPCR ligand binding—DRD4—conduct disorder	9.71e-05	0.0021	CbGpPWpGaD
Trazodone—HTR2B—GPCR ligand binding—HTR2A—conduct disorder	9.23e-05	0.002	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—CGA—conduct disorder	9.1e-05	0.00197	CbGpPWpGaD
Trazodone—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	9.09e-05	0.00197	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—CGA—conduct disorder	9.08e-05	0.00197	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—CGA—conduct disorder	9.06e-05	0.00196	CbGpPWpGaD
Trazodone—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	9.02e-05	0.00196	CbGpPWpGaD
Trazodone—ADRA2A—GPCR ligand binding—DRD4—conduct disorder	9.02e-05	0.00196	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—CGA—conduct disorder	8.89e-05	0.00193	CbGpPWpGaD
Trazodone—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	8.47e-05	0.00184	CbGpPWpGaD
Trazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	8.32e-05	0.0018	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—CGA—conduct disorder	8.26e-05	0.00179	CbGpPWpGaD
Trazodone—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	8.08e-05	0.00175	CbGpPWpGaD
Trazodone—HTR2B—GPCR downstream signaling—DRD4—conduct disorder	8e-05	0.00173	CbGpPWpGaD
Trazodone—ABCB1—brain—conduct disorder	7.99e-05	0.014	CbGeAlD
Trazodone—HTR2A—SIDS Susceptibility Pathways—EP300—conduct disorder	7.85e-05	0.0017	CbGpPWpGaD
Trazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	7.73e-05	0.00168	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CGA—conduct disorder	7.66e-05	0.00166	CbGpPWpGaD
Trazodone—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	7.49e-05	0.00162	CbGpPWpGaD
Trazodone—HTR2C—GPCR ligand binding—HTR2A—conduct disorder	7.45e-05	0.00161	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—CGA—conduct disorder	7.4e-05	0.0016	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—DRD4—conduct disorder	7.26e-05	0.00157	CbGpPWpGaD
Trazodone—CYP3A4—Biological oxidations—COMT—conduct disorder	6.56e-05	0.00142	CbGpPWpGaD
Trazodone—CYP3A4—Biological oxidations—MAOA—conduct disorder	6.52e-05	0.00141	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	6.48e-05	0.00141	CbGpPWpGaD
Trazodone—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	6.47e-05	0.0014	CbGpPWpGaD
Trazodone—HRH1—GPCR ligand binding—HTR2A—conduct disorder	6.45e-05	0.0014	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—DRD4—conduct disorder	6.45e-05	0.0014	CbGpPWpGaD
Trazodone—ADRA1A—GPCR ligand binding—HTR2A—conduct disorder	6.33e-05	0.00137	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CGA—conduct disorder	6.21e-05	0.00135	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CGA—conduct disorder	6.18e-05	0.00134	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—WASF1—conduct disorder	6.14e-05	0.00133	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—DRD4—conduct disorder	5.89e-05	0.00128	CbGpPWpGaD
Trazodone—ADRA2A—GPCR ligand binding—HTR2A—conduct disorder	5.88e-05	0.00128	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—DRD4—conduct disorder	5.86e-05	0.00127	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—CGA—conduct disorder	5.84e-05	0.00127	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—DRD4—conduct disorder	5.6e-05	0.00121	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—DRD4—conduct disorder	5.59e-05	0.00121	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—DRD4—conduct disorder	5.48e-05	0.00119	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CGA—conduct disorder	5.37e-05	0.00116	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CGA—conduct disorder	5.35e-05	0.00116	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—CGA—conduct disorder	5.35e-05	0.00116	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CGA—conduct disorder	5.25e-05	0.00114	CbGpPWpGaD
Trazodone—HTR2B—GPCR downstream signaling—HTR2A—conduct disorder	5.22e-05	0.00113	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—DRD4—conduct disorder	5.1e-05	0.0011	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—DRD4—conduct disorder	5.09e-05	0.0011	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—DRD4—conduct disorder	5.08e-05	0.0011	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—DRD4—conduct disorder	4.98e-05	0.00108	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—WASF1—conduct disorder	4.98e-05	0.00108	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—WASF1—conduct disorder	4.95e-05	0.00107	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CGA—conduct disorder	4.88e-05	0.00106	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—HTR2A—conduct disorder	4.74e-05	0.00103	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—DRD4—conduct disorder	4.63e-05	0.001	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—WASF1—conduct disorder	4.3e-05	0.000932	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—WASF1—conduct disorder	4.29e-05	0.00093	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—DRD4—conduct disorder	4.29e-05	0.00093	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	4.23e-05	0.000917	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—WASF1—conduct disorder	4.21e-05	0.000913	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—HTR2A—conduct disorder	4.21e-05	0.000912	CbGpPWpGaD
Trazodone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	4.2e-05	0.000911	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—CGA—conduct disorder	4.04e-05	0.000875	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—WASF1—conduct disorder	3.91e-05	0.000848	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	3.84e-05	0.000833	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—HTR2A—conduct disorder	3.82e-05	0.000829	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—CGA—conduct disorder	3.8e-05	0.000825	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—HTR2A—conduct disorder	3.65e-05	0.000791	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—HTR2A—conduct disorder	3.58e-05	0.000776	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—DRD4—conduct disorder	3.48e-05	0.000754	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—DRD4—conduct disorder	3.46e-05	0.00075	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—COMT—conduct disorder	3.34e-05	0.000724	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—HTR2A—conduct disorder	3.32e-05	0.000721	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—MAOA—conduct disorder	3.32e-05	0.000719	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—HTR2A—conduct disorder	3.31e-05	0.000718	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—HTR2A—conduct disorder	3.25e-05	0.000705	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—HTR2A—conduct disorder	3.02e-05	0.000655	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—DRD4—conduct disorder	3e-05	0.000651	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—DRD4—conduct disorder	3e-05	0.00065	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—DRD4—conduct disorder	2.94e-05	0.000638	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—HTR2A—conduct disorder	2.8e-05	0.000607	CbGpPWpGaD
Trazodone—ADRA2A—Hemostasis—EP300—conduct disorder	2.79e-05	0.000604	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—DRD4—conduct disorder	2.73e-05	0.000593	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—COMT—conduct disorder	2.64e-05	0.000571	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—MAOA—conduct disorder	2.62e-05	0.000567	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CGA—conduct disorder	2.49e-05	0.000539	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—COMT—conduct disorder	2.41e-05	0.000524	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—MAOA—conduct disorder	2.4e-05	0.00052	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—HTR2A—conduct disorder	2.27e-05	0.000492	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—HTR2A—conduct disorder	2.26e-05	0.000489	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—HTR2A—conduct disorder	1.96e-05	0.000424	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—HTR2A—conduct disorder	1.92e-05	0.000416	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—COMT—conduct disorder	1.82e-05	0.000395	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—MAOA—conduct disorder	1.81e-05	0.000392	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—HTR2A—conduct disorder	1.78e-05	0.000387	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—COMT—conduct disorder	1.72e-05	0.000372	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—MAOA—conduct disorder	1.71e-05	0.00037	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—EP300—conduct disorder	1.48e-05	0.000321	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—EP300—conduct disorder	1.43e-05	0.000311	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—EP300—conduct disorder	1.2e-05	0.000261	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—EP300—conduct disorder	1.2e-05	0.000259	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—EP300—conduct disorder	1.13e-05	0.000245	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—COMT—conduct disorder	1.12e-05	0.000243	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—MAOA—conduct disorder	1.11e-05	0.000242	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—EP300—conduct disorder	1.04e-05	0.000225	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—EP300—conduct disorder	1.04e-05	0.000225	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—EP300—conduct disorder	1.04e-05	0.000225	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—EP300—conduct disorder	1.02e-05	0.00022	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—EP300—conduct disorder	9.45e-06	0.000205	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—EP300—conduct disorder	7.81e-06	0.000169	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—EP300—conduct disorder	7.36e-06	0.00016	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—EP300—conduct disorder	4.81e-06	0.000104	CbGpPWpGaD
